Display options
Cite
de França IR, Meneses-Santos D, Moreira GV, et al. Insulin signaling pathway in the masseter muscle of dexamethasone-treated rats. Interv Med Appl Sci. 2018;10(4):226-232doi: 10.1556/1646.10.2018.44.
de França, I. R., Meneses-Santos, D., Moreira, G. V., Lima, F. B., Carvalho, C. R. O., & Marçal, A. C. (2018). Insulin signaling pathway in the masseter muscle of dexamethasone-treated rats. Interventional medicine & applied science, 10(4), 226-232. https://doi.org/10.1556/1646.10.2018.44
de França, Igor Rabelo, et al. "Insulin signaling pathway in the masseter muscle of dexamethasone-treated rats." Interventional medicine & applied science vol. 10,4 (2018): 226-232. doi: https://doi.org/10.1556/1646.10.2018.44
de França IR, Meneses-Santos D, Moreira GV, Lima FB, Carvalho CRO, Marçal AC. Insulin signaling pathway in the masseter muscle of dexamethasone-treated rats. Interv Med Appl Sci. 2018 Dec;10(4):226-232. doi: 10.1556/1646.10.2018.44. PMID: 30792919; PMCID: PMC6376360.
Copy Download .nbib Format: NLM
Share it on

Interv Med Appl Sci. 2018 Dec;10(4):226-232. doi: 10.1556/1646.10.2018.44.

Insulin signaling pathway in the masseter muscle of dexamethasone-treated rats.

Interventional medicine & applied science

Igor Rabelo de França, Daniela Meneses-Santos, Gabriela Virginia Moreira, Fábio Bessa Lima, Carla Roberta de Oliveira Carvalho, Anderson Carlos Marçal

Affiliations

  1. Department of Medicine, Center of Biological Sciences and Health, Federal University of Sergipe, Aracaju, Brazil.
  2. Department of Morphology, Center of Biological Sciences and Health, Federal University of Sergipe, São Cristóvão, Brazil.
  3. Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

PMID: 30792919 PMCID: PMC6376360 DOI: 10.1556/1646.10.2018.44

Abstract

BACKGROUND AND AIMS: The treatment with glucocorticoids may induce molecular changes in the level and/or degree of phosphorylation of proteins located downstream of the insulin receptor/insulin-like growth factor receptor (IR/IGF1R) in many tissues. However, few studies have investigated the intracellular insulin pathway in the masseter muscle. Therefore, this study aimed to analyze the IR/IGF1R signaling pathway in the masseter muscle of rats treated with dexamethasone.

MATERIALS AND METHODS: Male Wistar rats were divided into two groups: control group (intraperitoneally injected with 0.9% NaCl solution) and dexamethasone group [intraperitoneally injected with 1 mg/kg (bw) dexamethasone solution] for 10 consecutive days. Sections of the masseter muscle were removed at time zero and after the infusion of regular insulin into the portal vein.

RESULTS: Dexamethasone administration induces body weight loss without changing masseter muscle weight and reduces the expression of total IR and PI3K proteins; total levels of IRS1, Akt, and ERK1 remain unchanged between groups. The degree of phosphorylation/activity of IRS1 after insulin stimulus increased only in the control group; degree of phosphorylation of Akt increased in both groups, but this increase was attenuated in the dexamethasone group.

DISCUSSION AND CONCLUSION: The degree of phosphorylation/activity in the masseter muscle is different from that in other muscle territories.

Keywords: diabetes mellitus; glucocorticoids; masseter muscle; mastication; skeletal muscle

References

  1. J Biol Chem. 2000 Dec 15;275(50):38990-4 - PubMed
  2. Nature. 2001 Dec 13;414(6865):799-806 - PubMed
  3. Biochem Soc Trans. 2002 Apr;30(2):317-22 - PubMed
  4. Diabetologia. 2002 Nov;45(11):1475-83 - PubMed
  5. Diabetologia. 2005 Oct;48(10):2119-30 - PubMed
  6. Trends Endocrinol Metab. 2006 Mar;17(2):72-8 - PubMed
  7. J Physiol. 2006 Nov 1;576(Pt 3):923-33 - PubMed
  8. Arch Oral Biol. 2007 Apr;52(4):305-8 - PubMed
  9. Am J Physiol Regul Integr Comp Physiol. 2007 Jun;292(6):R2225-33 - PubMed
  10. J Clin Endocrinol Metab. 2007 Nov;92(11):4332-9 - PubMed
  11. Eur J Pharmacol. 2008 Feb 26;581(1-2):64-70 - PubMed
  12. FASEB J. 2008 Jun;22(6):1672-83 - PubMed
  13. Arch Biochem Biophys. 2008 Jun 1;474(1):91-101 - PubMed
  14. Int J Obes (Lond). 2008 Sep;32(9):1431-7 - PubMed
  15. Eur J Clin Invest. 2009 Feb;39(2):81-93 - PubMed
  16. BMC Public Health. 2009 Mar 25;9:88 - PubMed
  17. Diabetes Care. 2009 Nov;32 Suppl 2:S157-63 - PubMed
  18. Endocrinology. 2010 Jan;151(1):85-95 - PubMed
  19. Eur J Appl Physiol. 2010 Mar;108(5):999-1007 - PubMed
  20. Diabetes Care. 1991 Mar;14(3):173-94 - PubMed
  21. Curr Top Microbiol Immunol. 2010;346:267-78 - PubMed
  22. J Endocrinol. 2011 Oct;211(1):55-64 - PubMed
  23. Skelet Muscle. 2011 Jan 24;1(1):4 - PubMed
  24. PLoS One. 2011;6(10):e26223 - PubMed
  25. Exerc Sport Sci Rev. 2012 Oct;40(4):204-10 - PubMed
  26. Mol Cell Endocrinol. 2013 Nov 5;380(1-2):32-40 - PubMed
  27. Crit Rev Biochem Mol Biol. 2014 Jan-Feb;49(1):59-68 - PubMed
  28. PLoS One. 2015 Jun 08;10(6):e0128263 - PubMed
  29. Oxid Med Cell Longev. 2016;2016:4374671 - PubMed
  30. Nat Rev Dis Primers. 2015 Jul 23;1:15019 - PubMed
  31. Curr Obes Rep. 2016 Sep;5(3):320-6 - PubMed
  32. Metabolites. 2016 Aug 03;6(3):null - PubMed
  33. J Cell Physiol. 2017 Mar;232(3):650-664 - PubMed
  34. Obesity (Silver Spring). 2017 Feb;25(2):378-383 - PubMed
  35. J Diabetes Res. 2017;2017:1683678 - PubMed
  36. Cleve Clin J Med. 2017 Jul;84(7 Suppl 1):S4-S14 - PubMed
  37. Br Med J (Clin Res Ed). 1986 Aug 2;293(6542):299-303 - PubMed
  38. J Clin Invest. 1993 Oct;92(4):2065-72 - PubMed
  39. FEBS Lett. 1995 Dec 27;377(3):353-7 - PubMed

Publication Types